FDA Research Collaboration Agreement
Making use of publicly releasable FDA data to make improvements to our software
The FDA RCA (Research Collaboration Agreement) is a 5-year project between Lhasa Limited and the FDA/CDER (U.S. Food and Drug Administration’s Center for Drug Evaluation and Research).
The agreement aims to make use of publicly releasable FDA data to make improvements to software from Lhasa Limited.
Initiated in November 2011, following the agreements 5-year completion in 2016, the RCA was extended for an additional 5-years, to November 2021. Effective from November 2021, the term of the RCA was extended again for an additional five years to the new expiration date of November 2026.
The RCA was initiated on culmination of previous 5-year agreements and aims to make use of publicly releasable FDA data to construct, improve and validate our software for toxicity, metabolism, chemical degradation, and impurity purge factor prediction.
The following points provide a greater insight into the collaboration between us (Lhasa Limited) and the U.S. Food & Drug Administration (FDA):
We have always worked on the basis of ‘shared knowledge, shared progress’ and it is at the heart of our charitable purpose. Our collaboration with the FDA aligns with this premise, ensuring that the sharing of knowledge benefits both the public and the broader scientific community.
The FDA shares publicly releasable data sets with Lhasa Limited. This data, combined with our curated data sets harvested from literature and our member data, is then used to train, and improve our software solutions.
The FDA use their non-publicly releasable data sets to evaluate and provide feedback on the performance of our tools.
To date, FDA/CDER has shared publicly releasable data with us for a variety of toxicity endpoints including:
As part of this collaboration, the FDA provides feedback and guidance on our developments from a regulatory perspective, and these are shared with the scientific community through joint publications.
Work carried out under this collaboration also includes exploitation of in vitro and other relevant data, in addition to in vivo DART* information towards the prediction of molecular initiating events relevant to teratogenicity. This initiative looks to provide predictions over a significantly wider chemical space.
*DART (Developmental and Reproductive Toxicology Database)
There are numerous benefits to this collaboration including:
Continuous industry-led improvement
Through collaboration with the FDA, our software is consistent with FDA requirements. This offers peace of mind when submitting predictions from our software to regulators.
Shared knowledge, shared knowledge
The science explored, and any corresponding features and findings generated, from this collaboration are often shared with the wider scientific community through publications in journals or at relevant conferences.
Mining of publicly releasable FDA data sets has led to the development of new alerts in Derek Nexus, which provides users with a more robust prediction.
The best of both worlds: combining a defined approach and read-across to predict skin sensitisation potency
New approach methodologies (NAMs) are non-animal methods – including in chemico/in vitro assays and in silico predictions – which are increasingly being …
We are delighted to announce our participation in the Animal-Free Safety Assessment for Cosmetics (AFSA) Masterclass. Launched in March 2023, this free, …
We are delighted to share our vital new article ‘Establishing best practice for the application and support of solubility purge factors’ which …